EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
A small subset of patients with nonsmall cell lung cancer (NSCLC) harbors mutations in the epidermal growth factor receptor (EGFR) that predict unique sensitivity to EGFR tyrosine kinase inhibitors (TKIs). The characteristics and behavior of brain metastases (BMs) in these patients have not been well described. The longitudinal records of all NSCLC patients who underwent EGFR mutation screening at our center from August 2004 to November 2008 were reviewed for eligibility, and 93 patients were identified who developed BM during the course of their disease. Survival was estimated using the Kaplan-Meier method and the log-rank test. Multivariable predictors were assessed via the Cox proportional hazards model. Among the 93 patients with BM, 41 (44%) had mutations in EGFR, including 13 exon 19 deletions and 12 L858R mutations. Eighty-three percent of patients with BM were treated initially with whole brain radiation, either alone (53%) or in combination with craniotomy for neurosurgical resection (22%) or stereotactic radiosurgery (8%). Median survival from the time of BM was 11.7 months and was longer for patients with an EGFR mutation (14.5 vs 7.6 months, P = .09). On multivariable analysis, EGFR mutation (HR: 0.50, 95% CI: 0.30-0.82), age (HR: 1.03, 95% CI: 1.00-1.05), and active extracranial disease (HR: 3.30, 95% CI: 1.70-6.41) were independently associated with survival. In NSCLC patients with BM, EGFR mutation status is associated with improved survival, independent of age, functional status, extracranial disease status, and number of BMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 1×
“0 Gender Male 18 (44) 13 (25) 31 (33) Female 23 (56) 39 (75) 62 (67) Race Caucasian 37 (90) 49 (94) 86 (93) African American 0 (0) 0 (0) 0 (0) Asian 2 (5) 3 (6) 5 (5) Other 2 (5) 0 (0) 2 (2) Histology Adenocarcinoma 40 (98) 47 (90) 87 (94) Squamous 0 (0) 1 (2) 1 (1) Large Cell 1 (2) 0 (0) 1 (1) Other 0 (0) 4 (8) 4 (4)…”
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · cited 1×
“1 Karnofsky performance status ≥70 35 (85) 47 (90) 82 (88) ,70 6 (15) 5 (10) 11 (12) Prior chemotherapy 0 25 (61) 29 (56) 54 (58) 1 6 (15) 13 (25) 19 (20) 2 3 (7) 4 (8) 7 (8) 3 or more 7 (17) 6 (11) 13 (14) Prior EGFR TKI Yes 12 (29) 6 (12) 18 (19) No 29 (71) 46 (88) 75 (81) Status of primary tumor Active 29 (71) 35 (…”
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., McKenna, W. G., & Byhardt, R. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00619-0 · Cited by 2,544
Fossella, F., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.046 · Cited by 939
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820 · cited 2×
“3 22 (54) 15 (29) 37 (40) Unknown 1 (2) 1 (2) 2 (2) Hemorrhagic brain metastases Yes 6 (15) 10 (19) 16 (17) No 33 (80) 41 (79) 74 (80) Unknown 2 (5) 1 (2) 3 (3) Eichler et al.”
Self-citationHan, S.-W., Kim, T.-Y., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., Oh, D.-Y., Kim, J. H., Kim, D.-W., Chung, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.388 · Cited by 768
Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0793 · Cited by 695
Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y., & Nukiwa, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4692 · Cited by 509
Mehta, M. P., Rodrigus, P., Terhaard, C. H. J., Rao, A., Suh, J., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M., Komaki, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.122 · Cited by 463
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
Ceresoli, G. L., Cappuzzo, F., Gregorc, V., Bartolini, S., Crinò, L., & Villa, E. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh276 · Cited by 349
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.
Sørensen, J. B., Hansen, H. H., Hansen, M., & Dombernowsky, P. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.9.1474 · Cited by 339
on behalf of the Hokkaido Lung Cancer Clinical Study Group, Asahina, H., Yamazaki, K., Kinoshita, I., Sukoh, N., Harada, M., Yokouchi, H., Ishida, T., Ogura, S., Kojima, T., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603393 · Cited by 277
Das, A. K., Sato, M., Story, M. D., Peyton, M., Graves, R., Redpath, S., Girard, L., Gazdar, A. F., Shay, J. W., Minna, J. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2627 · Cited by 216
Kim, J.-E., Lee, D. H., Choi, Y., Yoon, D. H., Kim, S.-W., Suh, C., & Lee, J.-S. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2008.12.011 · Cited by 216
Hotta, K., Kiura, K., Ueoka, H., Tabata, M., Fujiwara, K., Kozuki, T., Okada, T., Hisamoto, A., & Tanimoto, M. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.04.036 · Cited by 176
Paz-Ares, L., Sanchez, J. M., García-Velasco, A., Massuti, B., López-Vivanco, G., Provencio, M., Montes, A., Isla, D., Amador, M. L., & Rosell, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7020 · Cited by 164
Das, A. K., Chen, B. P., Story, M. D., Sato, M., Minna, J. D., Chen, D. J., & Nirodi, C. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0242 · Cited by 160
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain
Wu, C., Li, Y. L., Wang, Z. M., Li, Z., Zhang, T. X., & Wei, Z. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.03.011 · Cited by 148
Gow, C.-H., Chien, C.-R., Chang, Y.-L., Chiu, Y.-H., Kuo, S.-H., Shih, J.-Y., Chang, Y.-C., Yu, C.-J., Yang, C.-H., & Yang, P.-C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1468 · Cited by 146 · cited 1×
“0 Gender Male 18 (44) 13 (25) 31 (33) Female 23 (56) 39 (75) 62 (67) Race Caucasian 37 (90) 49 (94) 86 (93) African American 0 (0) 0 (0) 0 (0) Asian 2 (5) 3 (6) 5 (5) Other 2 (5) 0 (0) 2 (2) Histology Adenocarcinoma 40 (98) 47 (90) 87 (94) Squamous 0 (0) 1 (2) 1 (1) Large Cell 1 (2) 0 (0) 1 (1) Other 0 (0) 4 (8) 4 (4)…”
Chiu, C., Tsai, C., Chen, Y., Chiang, S.-C., Liou, J.-L., & Perng, R.-P. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.05.014 · Cited by 143
Namba, Y., Kijima, T., Yokota, S., Niinaka, M., Kawamura, S., Iwasaki, T., Takeda, Y., Kimura, H., Okada, T., Yamaguchi, T., et al. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.026 · Cited by 138
Cappuzzo, F., Ardizzoni, A., Parra, H. J. S., Gridelli, C., Maione, P., Tiseo, M., Calandri, C., Bartolini, S., Santoro, A., & Crinò, L. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00189-2 · Cited by 116
Shimato, S., Mitsudomi, T., Kosaka, T., Yatabe, Y., Wakabayashi, T., Mizuno, M., Nakahara, N., Hatano, H., Natsume, A., Ishii, D., et al. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-002 · Cited by 95
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC
Lai, C. S. L. (2005) · Thorax · doi:10.1136/thx.2005.052233 · Cited by 82
Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients
Sequist, L. V., Joshi, V. A., Jänne, P. A., Bell, D. W., Fidias, P., Lindeman, N. I., Louis, D. N., Lee, J. C., Mark, E. J., Longtine, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0099 · Cited by 81
Self-citationRecurrent responses to non-small cell lung cancer brain metastases with erlotinib
Popat, S., Hughes, S., Papadopoulos, P., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.11.009 · Cited by 47
Gounant, V., Wislez, M., Poulot, V., Khalil, A., Lavolé, A., Cadranel, J. L., & Milleron, B. J. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.07.010 · Cited by 40
Brain Metastasis Responding to Gefitinib Alone
Poon, A., Ho, S. S. M., Yeo, W., & Mok, T. S. K. (2004) · Oncology · doi:10.1159/000081005 · Cited by 36
Gridelli, C., Maione, P., Galetta, D., Colantuoni, G., Gaizo, F. D., Ferrara, C., Guerriero, C., Nicolella, D., & Rossi, A. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3180cc25b0 · Cited by 35
CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation
Pan, M., Santamaria, M., & Wollman, D. B. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0931 · Cited by 18
Cited by
The biology of brain metastases—translation to new therapies
Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.58 · Cited by 567
Self-citationBrain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E., Mahadevan, A., Floyd, S. R., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 534
Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349
“Moreover, all patients in our series had worsening CNS metastases during or following treatment with an EGFR TKI at standard dosing, which was not addressed in the Eichler series.(10) Heon et al.”
BackgroundPeters, S., Bexelius, C., Munk, V., & Leighl, N. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.009 · Cited by 295
Stereotactic radiosurgery in the treatment of brain metastases: The current evidence
Lippitz, B., Lindquist, C., Paddick, I., Peterson, D., O’Neill, K., & Beaney, R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.002 · Cited by 261
Metadata
- Authors
- Eichler, A. F., Kahle, K. T., Wang, D. L., Joshi, V. A., Willers, H., Engelman, J. A., Lynch, T. J., & Sequist, L. V.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-07-13
- Volume
- 12
- Issue
- 11
- Pages
- 1193-1199
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2168856723
- Cited by
- 263
- References
- 38
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.